TOMI Environmental Solutions Secures UK CES contract integrating SteraMist iHP into Total Clean Air's Modular Cleanroom Platform
Rhea-AI Summary
TOMI Environmental Solutions (NASDAQ: TOMZ) announced on Jan 20, 2026 the sale of a Custom Engineered System (CES) in the United Kingdom to an international pharmaceutical manufacturer. The CES integrates SteraMist iHP into Total Clean Air's modular cleanroom platform, the first deployment of iHP within that architecture. The integration is described as regulator-ready for MHRA and EMA expectations and intended to provide a repeatable, scalable decontamination model across pharmaceutical cleanrooms.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus
Pre-news, TOMZ was down 1.14% with light volume, while peers were mixed: LIQT -2.78%, CLIR -3.72%, CLWT +5.49%, DEVS +4.72%, ZONE +3.26% (and separately flagged at -9.76% in momentum data). Movements do not show a unified sector direction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Product deployment | Positive | -3.0% | SteraMist Hybrid System installed at an East Coast research university. |
| Dec 22 | Facility adoption | Positive | +2.2% | Cell and gene therapy manufacturer adopted multi-stage SteraMist iHP systems. |
| Dec 18 | Large purchase order | Positive | -0.1% | Approximate <b>$500,000</b> SteraMist iHP purchase order from biopharma leader. |
| Dec 15 | Sector outreach | Positive | -5.1% | Company urged cruise lines to adopt hospital-grade SteraMist decontamination. |
| Dec 04 | Investor conference | Positive | -0.3% | Announcement of presentation at the 2025 Sidoti Year End Investor Conference. |
Recent positive news headlines have often been followed by weak or negative next-day price reactions.
Over the past few months, TOMI reported several SteraMist deployments and corporate updates. On Dec 4, 2025 it announced participation in the Sidoti conference, followed by multiple positive commercial wins in December, including a $500,000 SteraMist iHP integration and a cell and gene therapy facility implementation. A research university SteraMist Hybrid installation was disclosed on Jan 6, 2026. Despite these seemingly constructive operational developments, four of the last five news days saw negative 24-hour price reactions.
Regulatory & Risk Context
The company has an active S-3 shelf filed on 2025-11-14, allowing it to offer up to $50,000,000 of various securities over time. As of the latest data, the shelf is not yet effective and shows 0 recorded usages, but it provides flexibility to raise capital for general corporate purposes once effective.
Market Pulse Summary
This announcement details a UK Custom Engineered System sale that embeds SteraMist iHP directly into Total Clean Air’s modular cleanroom platform, creating a repeatable, regulator-ready model for pharmaceutical facilities. It builds on prior SteraMist deployments in healthcare and biopharma settings. Investors may focus on how many additional CES deployments follow, the pace of international adoption, and any related capital-raising activity under the existing $50,000,000 shelf when evaluating longer-term impact.
Key Terms
gmp regulatory
ema regulatory
mhra regulatory
hvac technical
AI-generated analysis. Not financial advice.
FREDERICK, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced the sale of a Custom Engineered System (CES) in the United Kingdom to an international pharmaceutical manufacturing organization.
The system is being delivered as part of a bespoke, modular cleanroom platform designed, engineered, and validated by Total Clean Air Limited (“TCA”), one of the United Kingdom’s leading authorities in GMP, EMA, and UK regulatory-compliant clean air and containment solutions. SteraMist iHP has been fully integrated into TCA’s modular cleanroom architecture, marking the first deployment of iHP technology within TCA’s modular platform. This integration establishes a repeatable, scalable, and regulator-ready model for future pharmaceutical cleanroom developments across the UK and wider international markets.
TCA’s modular solution has been developed to align with UK MHRA and EMA expectations, embedding decontamination capability directly into the cleanroom lifecycle — from design and construction through qualification, validation, and ongoing operation. This approach ensures pharmaceutical operators benefit from assured compliance, operational resilience, and long-term facility performance, rather than bolt-on or post-handover solutions.
This project further reinforces TCA’s position as a trusted cleanroom delivery partner to pharmaceutical manufacturers, providing fully integrated solutions spanning cleanroom design, controlled environments, containment, HVAC, validation, and clean air strategy.
Phillip Godden, Chief Executive Officer of Total Clean Air, commented:
“At Total Clean Air, our role is to engineer certainty into pharmaceutical environments. Integrating SteraMist iHP directly into our modular cleanroom platform allows us to deliver a fully aligned, regulator-ready decontamination strategy that supports both UK and EMA expectations from day one.
This collaboration demonstrates how advanced decontamination technology, when properly embedded into cleanroom design and validation, enhances patient safety, operational confidence, and long-term compliance. We see this as a strong foundation for continued collaboration in the UK and internationally.”
Elissa (E.J.) Shane, Chief Operating Officer of TOMI Environmental Solutions, added:
“This CES deployment represents an important step in TOMI’s international growth strategy. Partnering with Total Clean Air enables SteraMist iHP to be embedded within a robust, high-quality modular cleanroom platform that is already aligned with stringent pharmaceutical regulatory frameworks.
By working with a specialist such as Total Clean Air, we are creating a scalable pathway for future system deployments while supporting pharmaceutical manufacturers with integrated, compliant decontamination solutions.”
The collaboration reflects a shared commitment to engineering-led design, regulatory integrity, and patient-focused outcomes, positioning both organizations to support the continued expansion of high-quality pharmaceutical manufacturing capacity in the UK and beyond.
About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association.
For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com.
About Total Clean Air Limited
Total Clean Air Limited is a UK-based clean air and controlled environments specialist, delivering design, build, validation, and lifecycle support for cleanrooms, containment laboratories, and critical ventilation systems. Operating across pharmaceutical, life sciences, healthcare, and advanced manufacturing sectors, Total Clean Air is recognised for its engineering-led approach, UKAS-accredited validation capability, and strong ‘We Care’ culture underpinning long-term client partnerships.
Forward-Looking Statements
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding expansion of UK and international markets and ability to achieve revenue growth. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:
John Nesbett/Rosalyn Christian
IMS Investor Relations
FAQ
What did TOMI (NASDAQ: TOMZ) announce on Jan 20, 2026 about SteraMist iHP in the UK?
How does the integrated SteraMist iHP fit Total Clean Air's modular cleanroom platform?
Does the TOMI and Total Clean Air solution meet UK and EU regulatory expectations?
Which customers or markets could benefit from TOMI's CES integration with TCA?
What strategic role did TOMI describe for this CES deployment in its business plans?
What operational advantages did Total Clean Air claim from embedding SteraMist iHP?
